Today, AxoGen Inc. (AXGN) Given New $12.00 Price Target at Wedbush

Today, AxoGen Inc. (AXGN) Given New $12.00 Price Target at Wedbush

AxoGen Inc. (NASDAQ:AXGN) had its target price upped by Wedbush from $10.00 to $12.00 in a research note issued on Monday. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 36.36% from the company’s current price.

Separately, Lake Street Capital cut AxoGen from a “buy” rating to a “hold” rating and set a $9.00 target price on the stock. in a research note on Thursday, November 3rd.

Shares of AxoGen (NASDAQ:AXGN) opened at 8.80 on Monday. The stock has a 50 day moving average price of $8.68 and a 200 day moving average price of $7.66. AxoGen has a 52 week low of $4.52 and a 52 week high of $9.88. The stock’s market capitalization is $289.50 million.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). AxoGen had a negative return on equity of 292.94% and a negative net margin of 33.02%. On average, equities research analysts expect that AxoGen will post ($0.38) EPS for the current year.

In other news, VP John P. Engels acquired 4,000 shares of the business’s stock in a transaction on Friday, October 7th. The shares were acquired at an average cost of $7.50 per share, with a total value of $30,000.00. Following the transaction, the vice president now owns 98,425 shares in the company, valued at approximately $738,187.50. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Amy Mcbride Wendell acquired 13,333 shares of the business’s stock in a transaction on Friday, October 7th. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $99,997.50. Following the completion of the transaction, the director now owns 13,333 shares in the company, valued at approximately $99,997.50. The disclosure for this purchase can be found here. 9.33% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Waddell & Reed Financial Inc. purchased a new stake in AxoGen during the second quarter valued at $1,371,000. State Street Corp purchased a new stake in AxoGen during the second quarter valued at $1,885,000. Rhumbline Advisers purchased a new stake in AxoGen during the second quarter valued at $132,000. Teachers Advisors Inc. purchased a new stake in AxoGen during the second quarter valued at $267,000. Finally, TFS Capital LLC purchased a new stake in AxoGen during the second quarter valued at $113,000. 54.43% of the stock is currently owned by institutional investors and hedge funds.

Related posts

Leave a Comment